11th Nov 2026 07:00
Verici Dx plc
(“Verici Dx” or the “Company”)
Conference attendance at Mello2026 Investor event
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that Verici Dx will be presenting and exhibiting at the Mello2026 investor event on Tuesday 17 November, which will be held at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY.
Sara Barrington, CEO, will be presenting at 12:25pm and 16:45pm on the day, providing an overview of the Company and strategy, as well as discussing the recent successful fundraise, which management anticipates will provide sufficient runway to achieve cash-flow breakeven by the end of 2027. No new information will be disclosed at the event, and a PDF of the presentation will be made available on the Company’s website at https://vericidx.com/investors/.
For further information and tickets for the Mello2026 conference, please visit the event website at https://www.melloevents.com/mellolondon2026.
Verici Dx plc
| www.vericidx.com | |
Sara Barrington, CEO | Via Walbrook PR | |
Julian Baines, Chairman |
| |
|
| |
Singer Capital Markets (Nominated Adviser & Joint Broker) | Tel: +44 (0)20 7496 3000 | |
Russell Cook / Anastassiya Eley / Harry Littlewood |
| |
|
| |
Oberon Capital (Joint Broker) | Tel: +44 (0)20 3179 0500 | |
Mike Seabrook / Heena Karani |
| |
|
| |
Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or [email protected] | |
Alice Woodings / Rachel Broad | Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393 | |
|
| |
| ||
Verici Dx
Verici Dx plc (AIM: VRCI) is a precision diagnostics company transforming care for transplant patients. The company combines transcriptomic analysis with proprietary tests with underlying technology based upon artificial intelligence to deliver predictive, actionable, data-driven intelligence that reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence.
Operating at the intersection of laboratory and data science, Verici Dx develops complex models that the Company believes answer the clinical questions that matter most with clarity and precision. All commercially available tests are built to rigorous scientific standards, validated across inclusive, and real-world patient populations to ensure clinical relevance and reliability. Verici Dx’s lead product, Tutivia™, is a post-kidney transplant test focused on early detection of acute rejection.
The company is UK headquartered in Cardiff for the UK, and in Franklin, Tennessee for the U.S. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.
Related Shares:
Verici Dx